论文部分内容阅读
目的:探讨中晚期原发性肝癌患者化疗过程中联合扶正化积丸辅助治疗的临床效果及对患者血液流变学、并发症的影响。方法:选取2014年1月—2016年6月在医院接受放化疗治疗的97例中晚期原发性肝癌患者,根据就诊单双号分为放疗组48例、联合组49例,两组患者均接受放射治疗及基础治疗,联合组加用扶正化积丸,对比两组的治疗效果及相关实验室指标。结果:联合组的总有效率79.59%、放疗组的70.83%,差异不具有统计学意义(P>0.05);治疗后,联合组的全血黏度低切、全血黏度中切、全血黏度高切、血沉测定值较治疗前显著的降低(P<0.05),联合组的全血黏度低切、全血黏度中切、全血黏度高切、血沉测定值低于放疗组(P<0.05);治疗过程中,联合组的恶心呕吐发生率28.57%、腹泻发生率18.37%、便秘20.41%、放射性皮炎20.41%均显著低于放疗组的47.92%、37.50%、39.58%、39.58%(P<0.05)。结论:中晚期原发性肝癌患者化疗过程中联合扶正化积丸辅助治疗有助于改善患者的血液流变学指标、降低不良反应程度及发生率。
Objective: To investigate the clinical effect of adjuvant therapy with Fuzhengji Jiwan in the course of chemotherapy of patients with advanced primary liver cancer and its effect on the hemorheology and complications of patients with advanced primary liver cancer. Methods: From January 2014 to June 2016, 97 patients with advanced primary hepatocellular carcinoma treated by radiotherapy and chemotherapy in our hospital were divided into radiotherapy group (48 cases) and combination group (49 cases) Receiving radiotherapy and basic treatment, the combined group with Fuzhenghua Ji Wan, compared the two groups of treatment and related laboratory indicators. Results: The total effective rate was 79.59% in the combination group and 70.83% in the radiotherapy group, the difference was not statistically significant (P> 0.05). After treatment, the low blood viscosity, the middle blood viscosity, the whole blood viscosity (P <0.05). In the combination group, the whole blood viscosity cut, the whole blood viscosity cut, the whole blood viscosity cut, the ESR value lower than the radiotherapy group (P <0.05) ). During the course of treatment, the incidence of nausea and vomiting was 28.57%, the incidence of diarrhea was 18.37%, the constipation was 20.41% and the radiation dermatitis was 20.41%, which was significantly lower than 47.92%, 37.50%, 39.58% and 39.58% (P <0.05). Conclusion: Adjuvant therapy of Fuzhengji Ji Wan during the chemotherapy of patients with advanced primary liver cancer can help to improve the patients’ hemorheology indexes and reduce the degree and incidence of adverse reactions.